We found that RP-B7-H3 CAR T cell-treated mice had higher levels of splenic TSCM (CD45RA+CD62L+), TCM (CD45RA-CD62L+) and tumor-infiltrated CAR T cells (CD3+CD45+), in addition to having fewer CAR T cells expressing markers associated with T-cell exhaustion (CD3+CD45+CTLA-4+/PD-1+) and higher pro-inflammatory cytokines/chemokines in tumor tissues, compared to mice treated with B7-H3 CAR T cells only (Fig. 4d–g). This evidence concerns the gene SELL and neoplasm.